The purpose of this study is to compare CVR in psoriasis patients receiving two types of treatments: methotrexate (MTX) and tumor necrosis factor inhibitor (TNF-i) and to evaluate the correlation between the Framingham score and QIMT. This evidence concerns the gene TNF and psoriasis.